Encode is a clinical-stage biopharmaceutical company developing novel therapies for a broad range of genetic diseases. The company's proprietary technology platform, which includes CRISPR/Cas9 gene editing, gene therapy, and gene regulation, enables the development of highly specific and durable treatments for patients with genetic disorders. Encode's lead program, ENCODE-101, is a gene therapy for the treatment of Dravet syndrome, a rare and severe form of epilepsy. The company is also developing therapies for other genetic diseases, including cystic fibrosis, Huntington's disease, and Angelman syndrome.